World-first genetic warning system for future pandemics and diseases launches in UK
A world-first genetic warning system for future pandemics and emerging diseases has been launched in the UK.
The surveillance programme, run by the UK Health Security Agency (UKHSA), will see experts rapidly checking NHS samples for pathogens that could lead to serious outbreaks.
Experts believe if such a system had been around pre-Covid-19, the virus would have been spotted much more quickly and there would have been early signs it was taking root in the UK.
Traditionally, genomic methods rely on scientists or medics knowing what virus or bacteria they are looking for when they test a swab sample.
But a more detailed method – known as metagenomics – means they do not need to know what the pathogen is, and they can test samples to find new ones.
This is a hugely exciting development which will increase our ability to respond at speed to new and emerging pathogens and will help to ensure that we are as prepared as possible to act quickly and effectively to protect the public from future threats
Professor Susan Hopkins, UKHSA
All this information is also now being fed to the UKHSA at a national level, bringing together samples from NHS hospitals across England to spot trends and emerging clusters of disease.
By significantly improving the identification of new outbreaks as well as enabling the source of an outbreak to be better understood, the UKHSA said predictions could also be made about the effectiveness of potential treatments, and any concerning mutations could be identified.
Professor Susan Hopkins, UKHSA chief medical adviser, said: 'Genomics has been a crucial aspect of the response to the Covid-19 pandemic from the very start, and the UK's enormous technical expertise in this area has allowed us to play a leading role in the identification and analysis of Covid-19 variants as they emerge.'
She said the new mSCAPE programme will allow 'us to use the UK's leading genomics capability to conduct community surveillance… for the first time anywhere in the world' and use the data to improve health globally.
She added: 'This is a hugely exciting development which will increase our ability to respond at speed to new and emerging pathogens and will help to ensure that we are as prepared as possible to act quickly and effectively to protect the public from future threats.'
The mSCAPE programme is another great example of how the UK is leading the world in this field
Professor Dame Sue Hill
Professor Dame Sue Hill, chief scientific officer for NHS England and senior responsible officer for NHS Genomics, said: 'Genomics is revolutionising the way we predict, prevent, diagnose and treat illness – whether it's diagnosing rare conditions in children more quickly, helping personalise cancer treatments to make them more effective, or identifying people at greater risk from kidney disease.
'The mSCAPE programme is another great example of how the UK is leading the world in this field.'
The programme is being led by UKHSA but also includes the University of Birmingham, University of Edinburgh, and the NHS Clinical Respiratory Metagenomics Network led by Guy's and St Thomas' NHS Foundation Trust.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
an hour ago
- Daily Mirror
UKHSA issues urgent health warning after walking outdoors
People have been urged to look out for ticks, small creatures that can carry a number of infections. Brits have been issued an urgent warning to take care when walking outdoors this summer due to a serious risk to health. The UK Health Security Agency (UKHSA) has shared guidance on how to stay safe from ticks. Ticks are tiny, spider-like creatures that live in undergrowth and latch on to animals including humans when they walk through long grass. They are becoming more prevalent in parts of the UK, mainly due to increasing numbers of deer. While feeding, they can transmit viruses and infections that cause disease, with the most common being Lyme disease. In a post made to X, the UKHSA said: 'Summer's a great time to get outside, but ticks love the outdoors too. 'If you're walking through grassy or wooded areas, take a look at our guidance to help you stay safe and be tick aware.' In an infographic, it explained what to do if you find a tick on your body. What to do if you've been bitten by a tick 'Remove ticks as soon as you find them,' it said. 'If you have a tick removal device, follow its instructions or use a pair of fine-tipped tweezers.' Next you need to grasp the tick 'as close to the skin as you can'. The UKHSA explained: 'Pull upwards firmly, making sure all of the tick is removed.' You then need to clean the bite area with soap and water, and keep an eye on it for a few weeks in case of 'any changes' The health authority warned: 'Look out for a spreading bullseye rash, which is a common symptom of Lyme disease three to 30 days after being bitten. 'If you become unwell, for example with a spreading circular rash, flu-like symptoms, nerve pain or a droop on one or both sides of the face within a few weeks of a tick bite, call your GP practice or NHS 111.' Other potential symptoms of Lyme disease include: A high temperature, or feeling hot and shivery Headache Muscle and joint pain Tiredness and loss of energy The NHS warns that some people who are diagnosed and treated for Lyme disease continue to have symptoms, like tiredness, aches and loss of energy, that can last for years. 'These symptoms are often compared to fibromyalgia and chronic fatigue syndrome,' it says. 'It's not clear why this happens to some people and not others. This means there's also no agreed treatment.' You should speak to a doctor if your symptoms come back, or do not improve, after treatment with antibiotics. To reduce the risk of being bitten by a tick in the first place, the NHS recommends you:
The Independent
an hour ago
- The Independent
Thousands of NHS patients ‘to be denied breakthrough Alzheimer's drugs'
Breakthrough drugs that slow the progression of Alzheimer's disease will reportedly be refused for use on the NHS this week in a blow to thousands of patients. The two drugs, Lecanemab and donanemab, slow down the decline in Alzheimer's patients' ability to carry out daily activities. The drugs' success in halting the progression of Alzheimer's was heralded as a 'new era' by campaigners and researchers. However, the National Institute for Health and Care Excellence (Nice) is expected to refuse to recommend them on the NHS, according to The Sunday Times. The regulator has already issued two decisions, one in October last year and another in March, saying they would not recommend the drugs for use on the NHS. A final decision will be published on Thursday. Both drugs already have UK drug licences, making them available privately. It is estimated that around 70,000 adults in England would have been eligible for treatment if the drugs had been approved. The regulator will reportedly turn down both drugs on the grounds of cost-effectiveness, with one insider telling The Sunday Times: 'It is the end of the road for these drugs on the NHS'. Lecanemab removes build-ups of the protein beta-amyloid from the brain. Trials showed that lecanemab can slow the progression of Alzheimer's by 27 per cent over 18 months if given to someone early on in the course of their decline. Donanemab, marketed as Kisunla in the UK, teaches the body's immune cells to recognise and remove the amyloid protein, which builds up in the brains of people with Alzheimer's disease. The protein build-ups are thought to be toxic to brain cells, leading to the symptoms of Alzheimer's, the Alzheimer's society has said. Lecanemab can, however, cause swelling and bleeding in the brain. In trials for Donanemab, a third of recipients experienced abnormalities in their brain scans caused by brain swelling and bleeding, NICE said. The drugs reportedly cost around £20,000 to £25,000, with the NHS being offered a lower price. Privately, the treatment costs between £60,000-80,000 per year, according to Alzheimer's Research UK. In a previous review by NICE in October 2024, director of medicines evaluation Helen Knight said: 'Donanemab could slow down cognitive decline by 4-7 months, but this is just not enough benefit to justify the additional cost to the NHS. The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources'. While the regulator said the decision would be disappointing for some, 'there are other treatments being developed'. Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said the decision to turn down the drugs would be 'deeply disappointing'. She added: 'These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.' The regulator NICE is due to publish the final draft guidance about the two drugs on Thursday. This leaves space for the decision to be challenged and sent to a review panel before the final guidance is published.
BBC News
2 hours ago
- BBC News
Herne Bay man has bladder tumours treated as NHS outpatient
A father-of-four has had bladder tumours removed as an outpatient at a Kent hospital through a pioneering new Payne, from Herne Bay, watched on-screen as surgeons removed a small tumour from his bladder via a procedure known as trans urethral laser 67-year-old, who underwent the procedure last week at Kent and Canterbury Hospital, says he was "absolutely blown over by the experience and the technology".Mr Payne had a previous tumour removed under general anaesthetic four years ago at an East Kent Hospitals University NHS Foundation Trust hospital. He said he was "a little bit nervous" before undergoing the new procedure, as he feared it might not be as effective."But it was exactly the same, just without the general anaesthetic," he said."I watched it on screen. I could see everything, and it was just like watching a documentary. I was even able to direct the consultant to where the tumour was." 'Major step forward' The procedure saw lead consultant for superficial bladder cancer, Georgios Papadopoulos, insert a thin flexible tube with a camera and light into Mr Payne's then took biopsies of the tumour before it was removed using a laser. Any remaining cancer cells were killed using chemotherapy. Mr Papadopoulos said: "This is a major step forward in how we treat patients with small tumours in their bladder."The Prostate Cancer Support Association Kent donated two laser machines, while the League of Friends of the Kent and Canterbury Hospital also helped provide funding.
